VCM
BBIO icon

Versant Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Versant Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.65K Buy
101
+79
+359% +$6.15K ﹤0.01% 2392
2026
Q2 		$1.64K Buy
22
+3
+16% +$210 ﹤0.01% 2584
2026
Q1 		$1.41K Buy
+19
New +$1.38K ﹤0.01% 2613
2025
Q4 		– Sell
-27
Closed -$1.4K – 2654
2025
Q3 		$1.4K Sell
27
-11
-29% -$536 ﹤0.01% 2468
2025
Q2 		$1.64K Hold
38
– – ﹤0.01% 2417
2025
Q1 		$1.31K Hold
38
– – ﹤0.01% 2323
2024
Q4 		$1.04K Hold
38
– – ﹤0.01% 2186
2024
Q3 		$967 Sell
38
-102
-73% -$2.68K ﹤0.01% 1751
2024
Q2 		$3.55K Buy
140
+102
+268% +$2.79K ﹤0.01% 1334
2024
Q1 		$1.18K Hold
38
– – ﹤0.01% 1500
2023
Q4 		$1.53K Hold
38
– – ﹤0.01% 1384
2023
Q3 		$1K Hold
38
– – ﹤0.01% 1526
2023
Q2 		$654 Buy
+38
New +$572 ﹤0.01% 1742

Other funds holding BBIO

CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Versant Capital Management's BBIO Position: Q3 2026 in Review

Versant Capital Management increased its BridgeBio Pharma (BBIO) stake by 359% in Q3 2026, buying an estimated $6.15K and bringing the position to 101 shares worth $6.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Versant Capital Management first reported a position in BBIO in Q2 2023 and has held it in 13 quarters since. 12 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Versant Capital Management held 101 shares of BridgeBio Pharma worth $6.65K as of Q3 2026.
  • Versant Capital Management bought 79 BridgeBio Pharma shares in Q3 2026, an estimated $6.15K.
  • BridgeBio Pharma made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2392 holding.
  • Versant Capital Management first reported a position in BridgeBio Pharma in Q2 2023 and has held it in 13 quarters since.
  • 12 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.